IDEAYA Biosciences (IDYA) News Today $22.18 -0.54 (-2.38%) Closing price 01/17/2025 04:00 PM EasternExtended Trading$22.29 +0.11 (+0.49%) As of 09:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Stock Holdings Lifted by JPMorgan Chase & Co.JPMorgan Chase & Co. grew its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 17.8% in the third quarter, according to its most recent filing with the SEC. The fund owned 79,780 shares of the company's stock after acquiring an additional 12,029 shares during the period. JJanuary 21 at 3:03 AM | marketbeat.comShort Interest in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Expands By 10.1%IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) was the target of a large increase in short interest in December. As of December 31st, there was short interest totalling 10,000,000 shares, an increase of 10.1% from the December 15th total of 9,080,000 shares. Approximately 12.9% of the company's stock are sold short. Based on an average trading volume of 889,000 shares, the short-interest ratio is currently 11.2 days.January 19 at 2:28 PM | marketbeat.comRoyal Bank of Canada Reiterates Outperform Rating for IDEAYA Biosciences (NASDAQ:IDYA)January 18 at 2:56 AM | americanbankingnews.comIdeaya stock touches 52-week low at $22.15 amid market challengesJanuary 17, 2025 | msn.comIDEAYA Biosciences (NASDAQ:IDYA) Hits New 1-Year Low - Here's WhyIDEAYA Biosciences (NASDAQ:IDYA) Hits New 1-Year Low - Should You Sell?January 17, 2025 | marketbeat.comRBC Capital Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)January 16, 2025 | markets.businessinsider.comIDEAYA Biosciences' (IDYA) "Outperform" Rating Reaffirmed at Royal Bank of CanadaRoyal Bank of Canada reissued an "outperform" rating and set a $61.00 target price on shares of IDEAYA Biosciences in a research note on Wednesday.January 15, 2025 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Earns Overweight Rating from Cantor FitzgeraldJanuary 15, 2025 | americanbankingnews.comIDEAYA Biosciences: Robust Pipeline and Financial Stability Drive Buy RatingJanuary 13, 2025 | markets.businessinsider.comCantor Fitzgerald Reaffirms Overweight Rating for IDEAYA Biosciences (NASDAQ:IDYA)Cantor Fitzgerald reissued an "overweight" rating on shares of IDEAYA Biosciences in a research note on Monday.January 13, 2025 | marketbeat.comAnalysts Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) PT at $53.67January 13, 2025 | americanbankingnews.comIDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate GuidanceJanuary 12, 2025 | prnewswire.comIDEAYA Biosciences (NASDAQ:IDYA) Hits New 1-Year Low - Should You Sell?IDEAYA Biosciences (NASDAQ:IDYA) Sets New 1-Year Low - What's Next?January 10, 2025 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the sixteen analysts that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation, thirteenJanuary 10, 2025 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Sees Strong Trading Volume - What's Next?IDEAYA Biosciences (NASDAQ:IDYA) Sees Large Volume Increase - Here's WhyJanuary 3, 2025 | marketbeat.comIdeaya enters license agreement for SHR-4849 with Jiangsu HengruiDecember 30, 2024 | markets.businessinsider.comIDEAYA Biosciences: Strategic Partnership and Promising Clinical Data Support Buy RatingDecember 30, 2024 | markets.businessinsider.comIDEAYA Biosciences (NASDAQ:IDYA) Sets New 52-Week Low - Here's WhyIDEAYA Biosciences (NASDAQ:IDYA) Sets New 1-Year Low - Should You Sell?December 30, 2024 | marketbeat.comIDEAYA Signs License Agreement For ADC SHR-4849 With Jiangsu Hengrui PharmaDecember 30, 2024 | markets.businessinsider.comIDEAYA Biosciences: Strategic Acquisition and Promising Clinical Data Drive Buy RecommendationDecember 29, 2024 | markets.businessinsider.comIDEAYA Enters License Deal With Hengrui Pharma To Develop SHR-4849 Worldwide Outside Of GreaterChinaDecember 29, 2024 | markets.businessinsider.comIDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid TumorsDecember 29, 2024 | prnewswire.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)December 27, 2024 | prnewswire.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by Jane Street Group LLCJane Street Group LLC trimmed its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 38.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 79,537 shares of the company's stock after selling 49,476 shares during the perioDecember 23, 2024 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Stock Holdings Increased by Geode Capital Management LLCGeode Capital Management LLC increased its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 9.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,945,455 shares of the company's stock after purchasing an additioDecember 22, 2024 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Bought by Barclays PLCBarclays PLC increased its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 188.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 181,170 shares of the company's stock after acquirDecember 21, 2024 | marketbeat.comWellington Management Group LLP Lowers Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Wellington Management Group LLP lessened its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 77.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,111 shares of theDecember 20, 2024 | marketbeat.comIDEAYA Biosciences (IDYA) Receives a Hold from Leerink PartnersDecember 18, 2024 | markets.businessinsider.comIdeaya announces IDMC recommendation for darovasertib, crizotinib combinationDecember 17, 2024 | markets.businessinsider.comIDEAYA Biosciences: Promising Pipeline and Strong Financials Make for a Buy RecommendationDecember 17, 2024 | markets.businessinsider.comIDEAYA Biosciences (NASDAQ:IDYA) Receives "Overweight" Rating from Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating on shares of IDEAYA Biosciences in a research note on Tuesday.December 17, 2024 | marketbeat.comWedbush Reiterates "Outperform" Rating for IDEAYA Biosciences (NASDAQ:IDYA)Wedbush reaffirmed an "outperform" rating and set a $52.00 price objective on shares of IDEAYA Biosciences in a research report on Tuesday.December 17, 2024 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Sees Large Drop in Short InterestIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) was the target of a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 8,930,000 shares, a decline of 11.2% from the November 15th total of 10,060,000 shares. Currently, 11.6% of the shares of the company are short sold. Based on an average daily trading volume, of 890,000 shares, the days-to-cover ratio is currently 10.0 days.December 17, 2024 | marketbeat.comIDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal MelanomaDecember 17, 2024 | prnewswire.comIDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 yearsDecember 16, 2024 | uk.finance.yahoo.comIDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung CancersDecember 16, 2024 | prnewswire.comState Street Corp Has $105.11 Million Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)State Street Corp raised its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 15.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,317,936 shares of the company's stock after purchasing anDecember 16, 2024 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Rating of "Moderate Buy" by BrokeragesIDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) has received an average recommendation of "Moderate Buy" from the sixteen research firms that are presently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation, thirteen haDecember 16, 2024 | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Hits New 1-Year Low - What's Next?IDEAYA Biosciences (NASDAQ:IDYA) Hits New 1-Year Low - Should You Sell?December 13, 2024 | marketbeat.comBNP Paribas Financial Markets Lowers Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)BNP Paribas Financial Markets lessened its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 62.2% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 28,149 shares of the company's stock after selling 46,315 shares durDecember 12, 2024 | marketbeat.comIDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024December 11, 2024 | prnewswire.comIdeaya Biosciences doses first patient in IDE161, Keytruda combination trialDecember 10, 2024 | markets.businessinsider.comIdeaya Biosciences nominates IDE892 as development candidateDecember 10, 2024 | markets.businessinsider.comIDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial CancerDecember 10, 2024 | prnewswire.comIDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 InhibitorDecember 9, 2024 | prnewswire.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)December 6, 2024 | prnewswire.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Purchased by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. grew its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 12.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 689,073 shares of the company's stock afteDecember 6, 2024 | marketbeat.com1,347,252 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Purchased by RA Capital Management L.P.RA Capital Management L.P. acquired a new position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,347,252 shares of the company's stDecember 5, 2024 | marketbeat.com200,000 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Acquired by RTW Investments LPRTW Investments LP acquired a new position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 200,000 shares of the company's stock, valued at approximately $6,336December 5, 2024 | marketbeat.comRedmile Group LLC Cuts Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)Redmile Group LLC lessened its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 10.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 681,150 shares of the company's stock after selling 78,366 shares during the quarterDecember 5, 2024 | marketbeat.com Get IDEAYA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. Email Address IDYA Media Mentions By Week IDYA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IDYA News Sentiment▼-0.030.49▲Average Medical News Sentiment IDYA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IDYA Articles This Week▼86▲IDYA Articles Average Week Get IDEAYA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Blueprint Medicines News Revolution Medicines News BridgeBio Pharma News Lantheus News Legend Biotech News Elanco Animal Health News Cytokinetics News Nuvalent News Grifols News TG Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IDYA) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEAYA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IDYA Stock Alerts